Johnson & Johnson (JNJ) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Johnson & Johnson financial statements at a glance

Johnson & Johnson reported revenue of $94.19 billion for fiscal year 2025 (ended December 31, 2025), up 6.0% from fiscal year 2024. Net income was $26.80 billion, a net margin of 28.5%, and diluted earnings per share were $11.03.

At the end of fiscal year 2025 it had total assets of $199.21 billion, total liabilities of $117.67 billion and shareholders' equity of $81.54 billion, with cash and short-term investments of $20.10 billion and total debt of $47.93 billion.

Its operations brought in $24.53 billion of cash; capital spending was $5.22 billion, leaving free cash flow of $19.31 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

JNJ logo

Johnson & Johnson

JNJUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
94.19B
Prev Year: 88.82B
YoY: +6.0%
Operating Revenue
94.19B
Prev Year: 88.82B
YoY: +6.0%
Total Unusual Items Excluding Goodwill
5.89B
Prev Year: -7.14B
YoY: +182.4%
Total Unusual Items
5.89B
Prev Year: -7.14B
YoY: +182.4%
Normalized EBITDA
35.16B
Prev Year: 31.93B
YoY: +10.1%
Tax Rate for Calcs
0.177
Prev Year: 0
Tax Effect of Unusual Items
1.04B
Prev Year: -1.12B
YoY: +193.1%
Cost of Revenue
30.26B
Prev Year: 27.47B
YoY: +10.1%
Gross Profit
63.94B
Prev Year: 61.35B
YoY: +4.2%
Operating Expense
38.34B
Prev Year: 39.20B
YoY: -2.2%
Selling General and Administrative
23.68B
Prev Year: 21.97B
YoY: +7.8%
Research and Development
14.66B
Prev Year: 17.23B
YoY: -14.9%
Operating Income
25.60B
Prev Year: 22.15B
YoY: +15.6%
Net Non Operating Interest Income Expense
85.00M
Prev Year: 577.00M
YoY: -85.3%
Non-operating Interest Income
1.06B
Prev Year: 1.33B
YoY: -20.7%
Non-operating Interest Expense
971.00M
Prev Year: 755.00M
YoY: +28.6%
Other Income Expense
6.89B
Prev Year: -6.04B
YoY: +214.0%
Gain on Sale of Securities
400.00M
Prev Year: -300.00M
YoY: +233.3%
Special Income Charges
5.49B
Prev Year: -6.84B
YoY: +180.2%
Restructuring and Mergers Acquisition
428.00M
Prev Year: 1.03B
YoY: -58.6%
Impairment of Capital Assets
81.00M
Prev Year: 211.00M
YoY: -61.6%
Other Special Charges
-6.00B
Prev Year: 5.60B
YoY: -207.1%
Other Non-operating Income (expense)
1.00B
Prev Year: 1.10B
YoY: -9.1%
Pre-tax Income
32.58B
Prev Year: 16.69B
YoY: +95.2%
Provision for Income Taxes
5.78B
Prev Year: 2.62B
YoY: +120.4%
Net Income Common Stockholders
26.80B
Prev Year: 14.07B
YoY: +90.6%
Net Income
26.80B
Prev Year: 14.07B
YoY: +90.6%
Net Income Including Non-Controlling Interests
26.80B
Prev Year: 14.07B
YoY: +90.6%
Net Income from Continuing Operations
26.80B
Prev Year: 14.07B
YoY: +90.6%
Diluted NI Available to Com Stockholders
26.80B
Prev Year: 14.07B
YoY: +90.6%
Basic EPS
11.13
Prev Year: 5.863
YoY: +89.8%
Diluted EPS
11.03
Prev Year: 5.79
YoY: +90.5%
Weighted Average Shares (basic)
2.41B
Prev Year: 2.41B
YoY: +0.0%
Weighted Average Shares (diluted)
2.43B
Prev Year: 2.43B
YoY: +0.0%
Total Expenses
68.60B
Prev Year: 66.67B
YoY: +2.9%
Net Income from Continuing and Discontinued Operation
26.80B
Prev Year: 14.07B
YoY: +90.6%
Normalized Income
21.96B
Prev Year: 20.09B
YoY: +9.3%
Interest Income
1.06B
Prev Year: 1.33B
YoY: -20.7%
Interest Expense
971.00M
Prev Year: 755.00M
YoY: +28.6%
Net Interest Income
85.00M
Prev Year: 577.00M
YoY: -85.3%
EBIT
33.55B
Prev Year: 17.44B
YoY: +92.4%
EBITDA
41.05B
Prev Year: 24.78B
YoY: +65.7%
Reconciled Cost of Revenue
30.26B
Prev Year: 27.47B
YoY: +10.1%
Reconciled Depreciation
7.50B
Prev Year: 7.34B
YoY: +2.2%
Net Income from Continuing Operation Net Minority Interest
26.80B
Prev Year: 14.07B
YoY: +90.6%
Values in USD

Johnson & Johnson key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$94.2B$88.8B$85.2B$80.0B$78.7B
Gross profit$63.9B$61.4B$58.6B$55.4B$55.3B
Operating income$25.6B$22.1B$23.4B$21.0B$20.9B
Net income$26.8B$14.1B$35.2B$17.9B$20.9B
Diluted EPS$11.03$5.79$13.72$6.73$7.81
Total assets$199.2B$180.1B$167.6B$187.4B$182.0B
Total liabilities$117.7B$108.6B$98.8B$110.6B$108.0B
Shareholders' equity$81.5B$71.5B$68.8B$76.8B$74.0B
Cash and short-term investments$20.1B$24.5B$22.9B$22.3B$31.6B
Total debt$47.9B$36.6B$29.3B$39.6B$33.8B
Operating cash flow$24.5B$24.3B$22.8B$21.2B$23.4B
Capital spending$5.2B$6.2B$5.0B$4.0B$3.7B
Free cash flow$19.3B$18.1B$17.8B$17.2B$19.8B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Johnson & Johnson's revenue in fiscal year 2025?

$94.19 billion, up 6.0% from $88.82 billion in fiscal year 2024.

How much profit does Johnson & Johnson make?

Johnson & Johnson reported net income of $26.80 billion for fiscal year 2025 (28.5% of revenue); operating income was $25.60 billion.

How much cash and debt does Johnson & Johnson have?

At the end of fiscal year 2025: cash and short-term investments of $20.10 billion and total debt of $47.93 billion.

What is Johnson & Johnson's free cash flow?

$19.31 billion in fiscal year 2025 (operating cash flow of $24.53 billion minus capital spending of $5.22 billion).

MoreJohnson & Johnson stock overviewJohnson & Johnson executive teamJohnson & Johnson shareholdersJohnson & Johnson revenue by segment
RelatedPharmaceutical Preparation Manufacturing industryManufacturing sectorAbbVie financialsNovartis financialsAstraZeneca financialsAmgen financialsPfizer financialsSanofi financials
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube